Cancer-specific research with genetics, genomics, molecular mechanisms, or biomarker science at its core.
JCGB considers laboratory, computational, population, translational, and clinical studies when that scientific anchor makes a substantive contribution to the research question, methods, and interpretation.
JCGB provides a focused home for research that explains how inherited and acquired molecular changes shape cancer, and for work that develops or evaluates biomarkers for a defined research or clinical purpose.
The journal connects cancer initiation, progression, heterogeneity, metastasis, treatment response, and resistance with biomarker discovery, characterisation, and validation. Manuscript fit is determined by the central scientific contribution, not by the use of a particular assay, dataset, or technique alone.
The following groups describe the journal's core scientific territory. They are representative rather than an exhaustive keyword list.
Somatic drivers, tumor-suppressor alterations, DNA repair, genomic instability, mutational processes, chromosomal alterations, inherited predisposition, and germline variant interpretation.
Clonal evolution, intratumor heterogeneity, metastasis, therapy-driven selection, acquired resistance, pharmacogenomics, molecular targets, and synthetic-lethal relationships.
Discovery, assay characterisation, analytical and clinical validation, context-of-use evaluation, and biomarkers for risk, detection, diagnosis, prognosis, prediction, monitoring, minimal residual disease, or response.
Epigenetics, transcriptomics, non-coding RNA, proteomics, metabolomics, multi-omics, functional genomics, model systems, single-cell and spatial genomics, and molecularly grounded microenvironment or immune research.
Scope examples identify scientific themes; they do not guarantee editorial acceptance.
Different study settings are considered when the cancer-genetics, molecular-mechanism, or biomarker contribution remains central and the evidence is appropriate to the claim.
The scientific anchor matters more than the discipline label. Use these boundaries before choosing a submission format.
AI and machine learning, imaging or radiogenomics, microbiome research, tumor-microenvironment studies, treatment-response studies, technology papers, and case-based work may fit when the cancer-genetics, molecular, or biomarker contribution is substantive and appropriately supported. For an uncertain case, ask a scope question before submission.
These questions illustrate the journal's scope; they are not article titles or promises of acceptance.
Suitable work may use several scholarly formats. The current Author Instructions control exact category names, eligibility, structure, and preparation requirements.
Before preparing a manuscript, consult the JCGB Author Instructions. If a specialised format is not clearly covered there, contact the publisher before submission.
The scope is relevant to researchers and professionals whose cancer work has a substantive genetic, genomic, molecular, or biomarker foundation.
Cancer geneticists and genomicists, molecular and translational oncology researchers, biomarker scientists, molecular pathologists, clinical laboratory researchers, and molecular epidemiologists.
Researchers interpreting cancer mechanisms, hereditary risk, molecular diagnostics, prognosis, treatment response, resistance, and biomarker evidence.
Bioinformaticians, computational and systems biologists, assay developers, and clinical or population researchers working with cancer-linked molecular data.
A manuscript is more likely to meet the journal's stated remit when all five questions can be answered clearly.
Review the current author instructions, then submit through ManuscriptZone. If the molecular or biomarker contribution is uncertain, contact the publisher before submission.